<SEC-DOCUMENT>0000950170-24-125921.txt : 20241113
<SEC-HEADER>0000950170-24-125921.hdr.sgml : 20241113
<ACCEPTANCE-DATETIME>20241113070026
ACCESSION NUMBER:		0000950170-24-125921
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		13
CONFORMED PERIOD OF REPORT:	20241113
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20241113
DATE AS OF CHANGE:		20241113

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARS Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001671858
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				811489190
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39756
		FILM NUMBER:		241451119

	BUSINESS ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130
		BUSINESS PHONE:		858-771-9307

	MAIL ADDRESS:	
		STREET 1:		11682 EL CAMINO REAL, SUITE 120
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92130

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Silverback Therapeutics, Inc.
		DATE OF NAME CHANGE:	20160412
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>spry-20241113.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-12T15:17:06.4478+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:spry="http://ars-pharma.com/20241113" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2022-02-16" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>8-K</title>
  <meta http-equiv="Content-Type" content="text/html"/>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_2bd59650-8195-44e4-b1a5-4c25699d2cc6" name="dei:EntityCentralIndexKey" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094">0001671858</ix:nonNumeric><ix:nonNumeric id="F_8078ef32-8095-4784-a2d8-8d85bc3076f8" name="dei:AmendmentFlag" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" format="ixt:fixed-false">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="spry-20241113.xsd"/></ix:references><ix:resources><xbrli:context id="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001671858</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-11-13</xbrli:startDate><xbrli:endDate>2024-11-13</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:4pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">UNITED STATES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Washington, D.C. 20549</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">FORM </span><span style="font-size:18pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ae80446-f1d9-4a40-bcd9-1bcb14e8a308" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:DocumentType"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">8-K</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:18pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">CURRENT REPORT</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to Section 13 or 15(d)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">of the Securities Exchange Act of 1934</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:12pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c64cb2ab-ec3c-4bbf-b5f1-68797c5350f7" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">November 13, 2024</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Date of Report (Date of earliest event reported)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="font-size:24pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ab9245a-1592-49fa-98a8-4a878e45773a" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityRegistrantName"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:24pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(Exact name of registrant as specified in its charter)</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_c0eabaa9-eb1b-4d6c-92bf-181e8afd59a7" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Delaware</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_53e96947-c88b-4475-8711-593d59522937" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityFileNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">001-39756</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_36cc84a1-6a64-4406-af2a-f3c8b08bd65c" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityTaxIdentificationNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">81-1489190</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(State or other jurisdiction</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">of incorporation)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Commission</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">File Number)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(IRS Employer</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Identification No.)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:50.5%;box-sizing:content-box;"/>
     <td style="width:1.02%;box-sizing:content-box;"/>
     <td style="width:48.48%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_c3f3e46b-b34d-48f9-891d-7d752c322696" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityAddressAddressLine1"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">11682 El Camino Real</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_2666731f-d3a3-41fe-8f06-23d9cf35af4c" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityAddressAddressLine2"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Suite 120</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span><ix:nonNumeric id="F_ea418407-8983-42c6-a5f7-612f007fb8bb" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityAddressCityOrTown"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">San Diego</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">, </span><span><ix:nonNumeric id="F_78c3fb09-85fe-4c16-b374-edfa6b8faeed" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">California</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d9082e8f-f9be-4970-9ffa-6fe96e0f9ed5" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityAddressPostalZipCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">92130</span></ix:nonNumeric></span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Address of principal executive offices)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(Zip Code)</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Registrant&#8217;s telephone number, including area code: </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5ff8fcea-60ff-43dc-848e-09bf48fafe91" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:CityAreaCode"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(858)</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span><span style="font-size:10pt;font-family:Times New Roman;"><ix:nonNumeric id="F_97a97db6-1327-4dbd-8a32-a7aec92c8081" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:LocalPhoneNumber"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">771-9307</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Not Applicable</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:8pt;font-family:Times New Roman;min-width:fit-content;">(Former name or former address, if changed since last report.)</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:3.28%;box-sizing:content-box;"/>
     <td style="width:96.72%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_74e2f487-699a-41de-8bfe-4b58c6c91b04" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_7e0a3ef2-1cd5-482d-95d9-accde7837f0b" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_b6c825ea-d151-4446-b060-a237f4d0fc0a" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></p></td>
    </tr>
    <tr style="height:11pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:11pt;font-family:'Calibri',sans-serif;"><ix:nonNumeric id="F_524ed97e-28c9-4d18-9ea7-3b41cb563650" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:34%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
     <td style="width:1%;box-sizing:content-box;"/>
     <td style="width:32%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Title of each class</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Trading</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Symbol(s)</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;border-bottom:1pt solid #ffffff03;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.007in;border-bottom:1pt solid #000000;padding-right:0.003in;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Name of each exchange</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">on which registered</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_d92368f2-c38c-4c4e-a151-2ce63b95094f" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:Security12bTitle"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Common Stock, $0.0001 par value per share</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_21c9e9d6-4605-4f7d-b05e-a43131cef167" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:TradingSymbol"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">SPRY</span></ix:nonNumeric></span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span><ix:nonNumeric id="F_784e40e1-d2c6-477e-8b83-4e2d2ce9e63f" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">The Nasdaq Stock Market LLC</span></ix:nonNumeric></span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule 12b&#8211;2 of the Securities Exchange Act of 1934 (&#167; 240.12b&#8211;2 of this chapter).</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Emerging growth company </span><span style="font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_db7af1c0-cc27-4da0-be98-a00f38b37b7c" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9746;</span></ix:nonNumeric></span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;"><ix:nonNumeric id="F_8092692a-94d5-4e60-9f77-aba1e0c1a906" contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:'Segoe UI Symbol',sans-serif;min-width:fit-content;">&#9744;</span></ix:nonNumeric></span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;border-bottom:0.75pt solid #000000;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;" id="s88fc7c5dc8f252f1a4d1160e76b498f0"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Item 2.02 Results of Operations and Financial Condition.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">On November 13, 2024, ARS Pharmaceuticals, Inc. (the &#8220;Company&#8221;) announced its financial results for the three and nine months ended September 30, 2024 in the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The information in this Item 2.02 of this Current Report on 8-K, including Exhibit 99.1, is furnished and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today&#8217;s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.</span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:18pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
    <tr style="visibility:collapse;">
     <td style="width:10%;box-sizing:content-box;"/>
     <td style="width:90%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Item 9.01</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Financial Statements and Exhibits.</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;"> </span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(d)</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:7%;box-sizing:content-box;"/>
     <td style="width:4.02%;box-sizing:content-box;"/>
     <td style="width:88.98%;box-sizing:content-box;"/>
    </tr>
    <tr style="word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:8pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Exhibit</span></p><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:1pt;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Number</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Description</span></p></td>
    </tr>
    <tr style="height:5.75pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">99.1</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:middle;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><a href="spry-ex99_1.htm"><span style="color:#0000ff;white-space:pre-wrap;text-decoration:underline;min-width:fit-content;">Press Release dated November 13, 2024.</span></a></p></td>
    </tr>
    <tr style="height:10.1pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="padding-top:0.003in;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:1pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;word-break:break-word;white-space:pre-wrap;">
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">104</span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">  </span></p></td>
     <td style="padding-top:0.003in;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">SIGNATURES</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:23%;box-sizing:content-box;"/>
     <td style="width:28.76%;box-sizing:content-box;"/>
     <td style="width:4%;box-sizing:content-box;"/>
     <td style="width:44.24%;box-sizing:content-box;"/>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-family:'Calibri',sans-serif;min-width:fit-content;">&#160;</span></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">ARS PHARMACEUTICALS, INC.</span></p></td>
    </tr>
    <tr style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:11pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Date: November 13, 2024</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">By:</span></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">/s/ Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Richard Lowenthal, M.S., MSEL</span></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;min-width:fit-content;">&#160;</span></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;min-width:fit-content;">President and Chief Executive Officer</span></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:1in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</span></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;"/>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>spry-ex99_1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html>
 <head>
  <title>EX-99.1</title>
 </head>
 <body style="margin: auto!important;padding: 8px;line-height: 1;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Exhibit 99.1</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><img src="img41264513_0.jpg" alt="img41264513_0.jpg" style="width:168px;height:65px;"></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Updates</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:13pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Commercial launch of</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">(epinephrine nasal spray) underway in the United States</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Supplemental NDA for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">1mg dose granted priority review by FDA; PDUFA target date set for March 6, 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Exclusive license agreement with ALK-Abell&oacute; to commercialize</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> in Europe, Canada and certain other geographies; ARS Pharma to receive $145 million in upfront payment with total deal consideration of up to $465 million plus double-digit royalties</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Well-capitalized with $349.6 million in cash, cash equivalents and short-term investments on a pro forma basis, supporting an operating runway of at least three years</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Company to host conference call and webcast today at 8:00 a.m. ET<br><br></font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SAN DIEGO &#x2013; November 13, 2024 &#x2013; </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from allergic reactions that could lead to anaphylaxis, today reported early progress on the U.S. commercial launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">epinephrine nasal spray) 2 mg for the treatment of Type I allergic reactions, including anaphylaxis, in adults and children who weigh &#x2265;30 kg (66 lbs.), as well as business highlights and financial results for the third quarter of 2024.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#x201c;The third quarter marked a transformative period for ARS Pharma, driven by the FDA approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the U.S. and the European Commission approval of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">EURneffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the European Union,&#x201d; stated Richard Lowenthal, President and CEO of ARS Pharmaceuticals. &#x201c;With strong demand among healthcare providers and patients for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> as the first and only needle-free epinephrine treatment, robust patient support systems in place, and favorable early payer discussions ongoing, we feel very good about the early momentum in our U.S. launch. We&#x2019;re also proud to have further expanded the reach of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> outside the U.S. by partnering with ALK-Abell&oacute;, a global leader in allergy product commercialization. Operationally, we stand very well positioned with a balance sheet that is further strengthened by the $145 million upfront payment from ALK, positioning us to execute our U.S. commercial plans and business goals to enable patients around the world to have access to this vital epinephrine treatment.&#x201d;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">U.S. commercial launch ongoing for neffy, the first and only needle-free epinephrine treatment for Type 1 allergic reactions, including anaphylaxis</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On August 9, 2024, the FDA approved </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">epinephrine nasal spray)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2 mg for the treatment of Type 1 allergic reactions, including anaphylaxis, in adults and children who weigh &#x2265;30 kg (66 lbs.). </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> was first available for shipment on September 23, 2024, and in early October, the U.S. sales force started in the field and </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">became broadly available in retail pharmacies.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Launch to date:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">More than 5,700 healthcare providers had been reached by the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">sales force</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">More than 1,700 healthcare providers submitted a prescription for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, using BlinkRx through </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffyConnect</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, a service that provides</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">patients</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">access and co-pay support, as well as free at-home delivery;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Of the physicians who prescribed </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, 80% were in the highest decile category;</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">More than 1,000 allergists enrolled in the </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> Experience Program, which enables physicians to administer </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">during their in-clinic allergy food challenges; and,</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Product presentations and contract discussions with several of the key payors are underway, with initial coverage decisions expected by yearend. </font></div></div><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">In September 2024, ARS Pharma submitted a supplemental New Drug Application (sNDA) for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">1 mg</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">for the treatment of Type I allergic reactions, including anaphylaxis, in adults and children who weigh 15 to 30 kg (33-66 lbs.). In November 2024, the FDA granted the sNDA priority review and assigned a Prescription Drug User Fee Act (PDUFA) target action date of March 6, 2025.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">On-track with global strategy to make neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174; </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">available worldwide</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">On August 22, 2024, the European Commission granted marketing authorization for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EUR</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(epinephrine nasal spray) for the emergency treatment of allergic reactions (anaphylaxis) in adults and children who weigh &#x2265;30 kg. On November 8, 2024, ARS Pharma announced an exclusive licensing agreement with ALK-Abell&oacute; to commercialize</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in Europe, Canada and certain other geographies outside the U.S. Under the terms of the agreement, ARS Pharma will receive an upfront payment of $145 million, and is eligible to receive up to an additional $320 million in sales, commercial and other milestones, as well as tiered double-digit royalties in the teens on net sales in the licensed territories.</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The regulatory submission for approval in Australia has been filed by CSL Seqirus under its license agreement with ARS Pharma. In addition, regulatory submissions in both China and Japan are expected to be completed in November by the respective partners in those geographies. In December, ARS Pharma plans to file for regulatory submission in the United Kingdom and Canada on behalf of ALK-Abell&oacute;, and additional regulatory filings by ARS Pharma and ALK</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">are anticipated in 2025 to further expand global patient reach with </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Clinical expansion of neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> for urticaria to begin in 2025</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharma plans to initiate an outpatient Phase 2b study of its intranasal epinephrine technology in patients with chronic spontaneous urticaria, a prevalent skin disease, who have been treated previously with antihistamines and experience frequent acute flares. The Phase 2b trial is expected to begin in early 2025, followed by a potential single pivotal efficacy trial.</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Third Quarter 2024 Financial Results</font></p><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Revenue: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Total revenue was $2.1 million for the quarter ended September 30, 2024, comprised of $0.6 million in net product revenue for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> sales, which reflects revenues from only one week following product launch in late September, and $1.5 million in collaboration revenue for the same period. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Research and Development (R&amp;D) Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">R&amp;D expenses were $4.4 million for the quarter ended September 30, 2024, the majority of which is comprised of product manufacturing costs prior to the commercial launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, other product development costs, and compensation costs. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Selling, General and Administrative (SG&amp;A) Expenses: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">SG&amp;A expenses were $19.3 million for the quarter ended September 30, 2024, which is mainly comprised of personnel expenses and costs associated with starting the commercial launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net Loss: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Net loss was $19.1 million for the quarter ended September 30, 2024. </font></div></div><div class="item-list-element-wrapper" style="margin-left:0.3402777777777778in;display:flex;margin-top:0;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:0.25in;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:4.058460402047169%;word-break:keep-all;display:inline-flex;justify-content:flex-start;">&#x2022;</font><div style="width:100%;display:inline;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash Position: </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Cash, cash equivalents and short-term investments were $204.6 million as of September 30, 2024. On a pro-forma basis, the Company&#x2019;s cash, cash equivalents and short-term investments balance was $349.6 million, adjusted for the $145 million upfront payment from ALK-Abell&oacute; in conjunction with the November 2024 licensing agreement. ARS Pharmaceuticals expects its capital to be sufficient to fund its current operating plan for at least three years. </font></div></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Conference Call and Webcast Details</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Management will host a conference call and webcast at 8:00 a.m. ET today, November 13, 2024. To access the webcast and slides, please visit the Events &amp; Presentations page in the Investors &amp; Media section of the Company&#x2019;s website. A replay of the webcast will be available for 30 days following the event. Dial-in information for conference participants may be obtained by registering for the event here.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is an intranasal epinephrine product for patients with Type I allergic reactions including food, medications, and insect bites that could lead to life-threatening anaphylaxis.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INDICATION AND IMPORTANT SAFETY INFORMATION FOR </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">(epinephrine nasal spray)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">INDICATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">2 mg is indicated for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">IMPORTANT SAFETY INFORMATION</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">It is recommended that patients are prescribed and have immediate access to two </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> nasal sprays at all times. In the absence of clinical improvement or if symptoms worsen after initial treatment, administer a second dose of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the same nostril with a new nasal spray starting 5 minutes after the first dose.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is for use in the nose only.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Advise patients when to seek emergency medical assistance for close monitoring of the anaphylactic episode and in the event further treatment is required.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Absorption of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may be affected by underlying structural or anatomical nasal conditions.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Administer with caution to patients who have heart disease; epinephrine may aggravate angina pectoris or produce ventricular arrhythmias. Arrhythmias, including fatal ventricular fibrillation, have been reported, particularly in patients with underlying cardiac disease or taking cardiac glycosides, diuretics, or anti-arrhythmics.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The presence of a sulfite in </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">should not deter use.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may alter nasal mucosa for up to 2 weeks after administration and increase systemic absorption of nasal products, including </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Patients with certain medical conditions or who take certain medications for allergies, depression, thyroid disorders, diabetes, and hypertension, may be at greater risk for adverse reactions.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Epinephrine can temporarily exacerbate the underlying condition or increase symptoms in patients with the following: hyperthyroidism, Parkinson&#x2019;s disease, diabetes, renal impairment. Epinephrine should be administered with caution in patients with these conditions, including elderly patients and pregnant women.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Adverse reactions to </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> may include throat irritation, intranasal paresthesia, headache, nasal discomfort, feeling jittery, paresthesia, fatigue, tremor, rhinorrhea, nasal pruritus, sneezing, abdominal pain, gingival pain, hypoesthesia oral, nasal congestion, dizziness, nausea, and vomiting.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">These are not all of the possible side effects of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">. To report suspected adverse reactions, contact ARS Pharmaceuticals Operations, Inc. at 1-877-MY-NEFFY (877-696-3339) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">For additional information on </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">, please see Full Prescribing Information at www.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Type I Allergic Reactions Including Anaphylaxis</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Type I allergic reactions are serious and potentially life-threatening events that can occur within minutes of exposure to an allergen and require immediate treatment with epinephrine, the only FDA-approved medication for these reactions. While epinephrine autoinjectors have been shown to be highly effective, there are well published limitations that result in many patients and caregivers delaying or not administering treatment in an emergency situation. These limitations include fear of the needle, lack of portability, needle-related safety concerns, lack of reliability, and complexity of the devices. There are approximately 40 million people in the United States who experience Type I allergic reactions. Of this group, over the last three years, approximately 20 million people have been diagnosed and treated for severe Type I allergic reactions that may lead to anaphylaxis, but (in 2023, for example) only 3.2 million filled their active epinephrine autoinjector prescription, and of those, only half consistently carry their prescribed autoinjector. Even if patients or caregivers carry an autoinjector, more than half either delay or do not administer the device when needed in an emergency.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About Urticaria</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Urticaria is a skin disorder that causes itchy hives and/or angioedema with an annualized incidence of 5 million in the U.S. About 40% of those cases become chronic urticaria, of which 50% are non-responsive to first-line antihistamine therapy. These non-responsive patients on stable therapy regimens can experience exacerbations or flares several times a year among acute cases, and even several times a week, including up to three or four emergency room visits per year. Angioedema is also a co-occurring symptom in about 33 to 67% of these patients. There are currently no approved community use treatments for acute flares experienced by urticaria patients on chronic regimens of antihistamines. ARS Pharmaceuticals is investigating </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for episodic symptomatic relief of these acute flares or exacerbations to improve the quality of life of urticaria patients. If </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">is approved for this indication, patients would have the option to quickly resolve exacerbations or flares at home without escalating to chronic use of systemic biologics that may have more serious side effects and benefit-risk considerations or visiting the emergency room for further treatment.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">About ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals is a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect patients from allergic reactions that could lead to anaphylaxis. The Company is commercializing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> 2 mg (trade name </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">EUR</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;vertical-align:super;font-size:8.040000000000001pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">&#174;</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in the EU) (previously referred to as ARS-1), an epinephrine nasal spray indicated in the U.S. for emergency treatment of Type I allergic reactions, including anaphylaxis, in adult and pediatric patients who weigh 30 kg or greater, and in the EU for emergency treatment of allergic reactions (anaphylaxis) due to insect stings or bites, foods, medicinal products, and other allergens as well as idiopathic or exercise induced anaphylaxis in adults and children who weigh 30 kg or greater. For more information, visit www.ars-pharma.com.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:4pt;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Forward-Looking Statements</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Statements in this press release that are not purely historical in nature are &#x201c;forward-looking statements&#x201d; within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to: the planned studies of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> for urticaria and timing thereof; ARS Pharmaceuticals&#x2019; projected cash runway and belief that it is well capitalized and prepared to support the ongoing launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the belief that the commercial launch of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> will progress through 2024 and into 2025; the expectation that payors will make coverage decisions as early as in [the fourth quarter of 2024]; ARS Pharmaceuticals&#x2019; plans regarding regulatory submissions in the United Kingdom, Canada, Japan and China; ARS Pharmaceuticals&#x2019; plans to enter into additional licensing and distribution agreements; the expected timing of the regulatory milestones under the agreement with ALK; the needle-free profile of </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> increasing the likelihood that patients will both carry and administer adrenaline; the potential market and demand for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy </font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">the potential benefits to urticaria patients if </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> is approved in this indication; and other statements that are not historical fact. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as &#x201c;anticipate,&#x201d; &#x201c;expects,&#x201d; &#x201c;if,&#x201d; &#x201c;may,&#x201d; &#x201c;potential,&#x201d; &#x201c;on track to,&#x201d; &#x201c;plans,&#x201d; &#x201c;will,&#x201d; &#x201c;would,&#x201d; and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon ARS Pharmaceuticals&#x2019; current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: potential safety and other complications from </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the labelling for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> in any future indication or patient population, if approved; the scope, progress and expansion of developing and commercializing </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the potential for payors to delay, limit or deny coverage for </font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">neffy</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">; the size and growth of the market therefor and the rate and degree of market acceptance thereof vis-&agrave;-vis intramuscular injectable products; ARS Pharmaceuticals&#x2019; ability to protect its intellectual property position; the impact of government laws and regulations; and the PDUFA target action date may be delayed due to various factors outside ARS Pharmaceuticals&#x2019; control. Additional risks and uncertainties that could cause actual outcomes and results to differ materially from those contemplated by the forward-looking statements are included under the caption &#x201c;Risk Factors&#x201d; in ARS Pharmaceuticals&#x2019; Quarterly Report on Form 10-Q for the quarter ended June 30, 2024, filed with the Securities and Exchange Commission (&#x201c;SEC&#x201d;) on August 6, 2024, and in ARS Pharmaceuticals&#x2019; Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, being filed with the SEC today. These documents can also be accessed on ARS Pharmaceuticals&#x2019; website at www.ars-pharma.com by clicking on the link &#x201c;Financials &amp; Filings&#x201d; under the &#x201c;Investors &amp; Media&#x201d; tab.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">The forward-looking statements included in this press release are made only as of the date hereof. ARS Pharmaceuticals assumes no obligation and does not intend to update these forward-looking statements, except as required by law.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">###</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="padding-top:0.5in;z-index:-3;min-height:1.12in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Investor Contacts:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Justin Chakma, ARS Pharmaceuticals<br>justinc@ars-pharma.com</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">  </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Alex Straus, THRUST</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">alex@thrustsc.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">Media Contact:</font><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"><br>Christy Curran, Sam Brown Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">christycurran@sambrown.com</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:1in;width:6.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:1in;"><div style="z-index:-3;flex-direction:column;display:flex;min-height:1in;justify-content:flex-end;position:relative;"></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Balance Sheets</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and par value data)</font><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:65.92%;box-sizing:content-box;"></td>
     <td style="width:1.6%;box-sizing:content-box;"></td>
     <td style="width:1.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.64%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.6%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:12.64%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">September 30, 2024</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">December 31, 2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">(unaudited)</font></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Assets</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current assets:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cash and cash equivalents</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">39,657</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">70,971</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Short-term investments</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">164,967</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">157,389</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts receivable, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">773</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Inventories</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">715</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Prepaid expenses and other current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,677</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,366</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">208,789</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">231,726</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Right-of-use asset</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">92</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">250</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Fixed assets, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">843</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">574</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Intangible assets, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">7,500</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">377</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">638</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total assets</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217,601</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Current liabilities:</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accounts payable and accrued liabilities (including related party amounts of $133 and $178, respectively)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,521</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,154</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, current</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">102</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">237</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total current liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,623</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,391</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Lease liability, net of current portion</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">37</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,623</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,428</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Commitments and contingencies</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Stockholders&#x2019; equity</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Preferred stock, $0.0001 par value per share; 10,000,000 shares authorized at September 30, 2024 and December 31, 2023; no shares issued and outstanding at September 30, 2024 and December 31, 2023</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Common stock, $0.0001 par value per share; 200,000,000 shares authorized at September 30, 2024 and December 31, 2023; 97,147,442 and 96,414,963 shares issued and outstanding at September 30, 2024 and December 31, 2023, respectively</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Additional paid-in capital</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">373,868</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">362,004</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated other comprehensive gain, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">339</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">49</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Accumulated deficit</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(173,239</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(131,303</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">200,978</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">230,760</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total liabilities and stockholders&#x2019; equity</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">217,601</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">233,188</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="padding-top:0.5in;z-index:-3;min-height:0.5in;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">ARS Pharmaceuticals, Inc.</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Condensed Consolidated Statements of Operations and Comprehensive Loss</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(in thousands, except share and per share data)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(unaudited)</font></p><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p>
   <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
    <tr style="visibility:collapse;">
     <td style="width:48.99%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.978%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:10.577%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.358%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:1.02%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
     <td style="width:9.058%;box-sizing:content-box;"></td>
     <td style="width:1%;box-sizing:content-box;"></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Three Months Ended September 30,</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="6" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">Nine Months Ended September 30,</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:8pt;background-color:#ffffff;word-break:break-word;white-space:pre-wrap;text-align:left;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2024</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="color:#000000;white-space:pre-wrap;font-weight:bold;min-width:fit-content;">2023</font></p></td>
     <td style="vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue:</font></p></td>
     <td style="vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Product revenue, net</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">568</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="font-size:8pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Revenue under collaboration agreements</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">1,500</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,000</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total revenue</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,068</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,568</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">30</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;">
     <td style="vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Operating expenses:</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td colspan="2" style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Cost of goods sold</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">112</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">&#x2014;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Research and development (including related party amounts of $406, $307, $1,651 and $1,382, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">4,423</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,002</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,553</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">16,862</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Selling, general and administrative (including related party amounts of $129, $322, $337 and $840, respectively)</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:top;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19,281</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">14,976</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">36,183</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">40,462</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Total operating expenses</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">23,816</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">17,978</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">52,848</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">57,324</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Loss from operations</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(21,748</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(17,978</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(50,280</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(57,294</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Other income, net</font></p></td>
     <td style="text-indent:10pt;white-space:pre-wrap;vertical-align:bottom;"><p style="margin-left:10pt;text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">2,620</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">3,112</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">8,344</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">10,097</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(19,128</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,866</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,936</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(47,197</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Change in unrealized gains and losses on available-for-sale securities</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">484</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">19</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">290</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(568</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Comprehensive loss</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(18,644</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(14,847</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(41,646</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(47,765</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#cff0fc;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.20</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.16</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.43</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">$</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">(0.50</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;min-width:fit-content;">)</font></p></td>
    </tr>
    <tr style="height:10pt;background-color:#ffffff;word-break:break-word;">
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">Weighted-average shares outstanding used in computing net loss per share, basic and diluted</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:top;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">97,032,331</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">95,576,627</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">96,782,818</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
     <td style="white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><font style="color:#000000;white-space:pre-wrap;min-width:fit-content;">94,910,012</font></p></td>
     <td style="white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="min-width:fit-content;">&#160;</font></p></td>
    </tr>
   </table><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div>
  <div class="fixed-width-container" style="margin-left:auto;padding-left:0.5in;width:7.5in;margin-top:auto;box-sizing:content-box;margin-right:auto;padding-right:0.5in;"><div style="z-index:-3;flex-direction:column;display:flex;padding-bottom:0.5in;min-height:0.5in;justify-content:flex-end;position:relative;box-sizing:border-box;"><p style="font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><font style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">&#160;</font></p></div></div>
  <hr style="margin-inline-start:auto;margin-inline-end:auto;width:8.5in;page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>img41264513_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img41264513_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $W R # 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8$)_4FOHL^C&CAJ=*"LK_DCYO()2K8JI5F[NV_S/1J***^'/O HHHH ****
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M_H?7<-1_BR]/U%HHHKXP^V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/[5;P_+J>MD.*]CB?9/:?Y]#]$J***_/#]'"BBB@ HHHH **** "OG;_ (*
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M@R21L,JRD=000:MU^5R;;;EN?K$4DDH[!1112*"BBB@ HHHH **** "BBB@
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MY(O5W;;/@,7URJ@"YF  P )6&/UI?[0NO^?J?_OZW^-?L[_PQA\$O^B<Z/\
M]\O_ /%4?\,8?!+_ *)SH_\ WR__ ,57A_ZP8?\ D?X?YGN_ZN8C^=?C_D?C
M%_:%U_S]3_\ ?UO\:/[0NO\ GZG_ ._K?XU^SO\ PQA\$O\ HG.C_P#?+_\
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M[CAW%7C+#2Z:K]3UBBBBOCS[0**** "BBB@ KYS_ ."@K;?V4/&(_O260_\
M)N&OHROFS_@H=+Y?[*GB@?W[FQ7_ ,FHS_2N[ _[W2_Q+\S@Q_\ NE7_  O\
MC\A****_63\A/N[_ ()1,/\ A,/B(OK869_\B2U^D%?FO_P2FDQ\0/'T?][3
M+9ORE;_&OTHK\TSK_?9_+\D?J&2?[C#Y_F%%%%>&>Z<1\8_A/HOQK^'FK>$M
M=3_1;U/W5PH!DMIEYCF3_:4\^XR#P37XH_$[X;ZW\(_'6K^$_$%OY&I:=+L+
M '9,AY25#W5EP1]<=0:_>6OEW]N?]ET?'/P.-?T&U5O&^AQ,ULJC#7UO]Y[<
M^K=63_:R/XB:^BR?,/JM3V51^Y+\'W_S/F\YR_ZU3]K37OQ_%?UL?DG6CX=\
M1:GX1UZPUO1KR73M5T^9;BVNH3AHW4Y!]_0@\$$@\&L]E:-F5U9'4D%6&"".
MH([&DK]$:4E9GYNFXNZW/VA_94_:4TS]H[X?I?#RK3Q/IX6'5]-4_P"KD(XE
M0=3&^"1Z'*GD5[;7X4_!GXP:]\#?'^G^*_#TN+FW/EW%K(2(KN D;X9/8X&#
MV(!'(K]GO@W\7?#_ ,</ 6G^*O#L_F6ER-LUNY'FVLPQOAD'9E/Y@@C@@U^;
MYKESP<^>G\#_  \O\C],RG,EC*?LZC]]?CY_YG<4445X)] %%%% !1110 5\
M\_"G]JY?B9^TEXZ^&,>C1VUEX?CE-OJ2S%GG>&5(I@RXP!N?Y<'HISUX^A:_
M*S]E/QPFD?M\:I+-)LAUW4]7L2Q/5GDDD0?BT:C\:];!8:->E6E)7<8W7]?(
M\?'8F>'JT(Q=E*5F?JI1117DGL!1110 4E+10!^*O[7WPQ@^$O[0OBO1;*(0
MZ7/*NHV4:C"I%,-^T>RL74>RUXW7V3_P5*LXH?CKX<G3 EF\/1B3_@-Q, ?R
M/Z5\;5^L9?4=7"TYRWL?D684U2Q=2$=KL[[]GY7D^//PX$8R_P#PD>GX_P#
MA*_="OQF_8?\)OXN_:@\$1*NZ+3[B34Y3_=6&-F4_P#?>P?C7[,5\CQ#-.O"
M/9?J?8<.0:H3GW?Y?\.+1117RI]:%%%% !1110 4444 %%%% !1110 4444
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M^6VTNQERQ[#?($4#\:_/?]IK]JCQ)^TIX@A>]3^R/#5DY:PT6&0NJ,>/-D;
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M_#O31_NR3#^3U$?V'/@8W_-/;'\+FX'_ +4KW?\ 6'#_ ,DOP_S/!_U<Q/\
M/'\?\C\L_@'^T!XG_9Y\9#7/#TJSVTX6/4-+N"?(O(P<@-C[K#)VN.02>H)!
M_1KP'_P4>^$'BFQA;6;V^\)7[#]Y;ZA:22HK>TL08$>Y"_05V!_87^!9_P":
M?68^EY=?_':9_P ,*? OK_PK^U_\#;K_ ..UY6+QV78Q\U2$E+NK?YGJX/ Y
ME@5R4YQ<>SO_ )'4>#?VHOA3\0->M-$\/^.-+U'5KLE;>S5F224@$D*&49.
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MZVWK<H/R3_Z]>R5_2'"JMDU#T?\ Z4SMI_"@HHHKZLT"BBDH 6BBB@ HHHH
M**** "BDS2T %%%% !1110 44E+0 4444 %%%% !1124 +1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFU7%U<1A\1\3?.D^SW7HM+>IC3E>Z9T%%%%?I9N%%%% !1110 4444 %%%%
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MKB_^%R>#?^@W'_WZD_\ B:/^%R>#?^@W'_WZD_\ B:]O^ULN_P"@B'_@4?\
M,OFCW.TKY3^,/_)2-:_WX_\ T6E>\?\ "Y/!W_0;C_[]2?\ Q-?/GQ*U:TUW
MQQJE_8S"XM)G0I( 0&PB@\'GJ#7Y]QICL+B<!3A0JQD^=:)I_9EV9C5::T/H
M[X7?\D]T#_KT2NIKEOA?_P D]T#_ *]$_E74U^BY;_N5#_!'\D;QV04445Z(
MR*XN([2WEGE8)%&I=V/8 9)KQ3X,QR>+O'FO^*KA<J"5BS_"7/ _!% _&NL^
M.?B,:'X'FMD?;<:@PMEYYV]7/Y#'_ JM_!G0?[!\!V&]=L]YF[DSU^;[O_CH
M6OC<5+Z]G=#"K6-%.I+_ !/2*]5N9O6278\#^(FAOX1\=:A!!F)5F%S;,.RL
M=RX^AR/PKZ<\(>($\4>&M/U-/^7B(,Z_W7'##\"#7EW[1GA_S+73-;C3F-C:
MS'_9/*'\P1_P*D_9T\2>9;ZCH4K<QG[5 #_=/#@?C@_\"-?,Y2_[&X@K8!Z0
MJZQ_-?K'U,X^[-H]KHHHK]8.@**** /C6^_Y&JY_Z_V_]&FOLJOC74/^1JN?
M^O\ ;_T::^RJ_*^!_BQ?K'_VXYZ74*X/XW6ZW'PWU,L,F)HI%^HD4?U-=Y7F
MOQ]U9+'P(UJ6 EO9TC5>Y"G>Q_\ '1^=?<9Y.$,LQ#GMR2_%67XFL_A9YC\
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MHT)[QC%/U22-XJR2"BBBN\84444 ?,GQX.?B-<_]>T/\C7LOP9/_ !;71?\
M=D'_ )$:O%?CE()/B1J !SLBA7_QP'^M>R?!"83?#?3 #DHTJG_OXW^-?DN0
MR7^LN,7^/_TM'/#^(SO****_6CH"BBB@ KYR_:(.?&UH/2Q3_P!#>OHVOFS]
MH&82>/E0'/EV<8/XLQ_K7P?&KME37>43&K\)Z5^S^V?A^OM=S?S%>DUYC^SU
M*'\"2H#RE[(#^(4_UKTZO=X?=\JPW^%%P^%!1117OEB5\I_%\Y^)&M_]=$_]
M%K7U;7R9\5)1-\1->8<@7&W\E4?TK\UX\?\ L%)?WU_Z3(PK;'T3\+3N^'>@
M?]>JUU5<A\))!-\.-"([0;?R8C^E=?7W&6/FP-!K^2/Y(UCL@KR;]H;Q']@\
M.6NDQOB6^EW28_YYI@G\VV_D:]9KYH\9WG_"R/BY%8Q/OM!.EE&P.1L4YD8?
MCO\ TKY_BK%RHX#ZO2^.LU!?/?\ #3YD5'[MNYZ_\&_#_P#PC_@.P#KMN+O-
MU)GK\_W1_P!\[:[BF1QK#&J(H5% 4*.P':GU]-@\-'!X>GAX;127W&B5E8*\
MI_:#\-_VCX9M]6B7,VGR?.0.?*? /Y':?SKU:J>KZ;#K&EW=A<+F"YB:)_H1
MBN?-,%',,%5PK^TM/7H_O%)<RL?/OP!\3?V3XLETR5\0:E'A<]/-7)7\QN'Y
M5]'5\921WGA7Q R9,5]IUSP?]M&X/T./UKZX\,Z_;^*-"LM3MCF.XC#;?[K?
MQ*?<'(_"OAN"<<Y4*F7U=)4W=+R>Z^3_ #,J4M+&K1125^FFY\:7[9\37)[?
M;F/_ )%-?9=?%EW,&U2>8<@W#/\ ^/DU]HPN)(D<=&4']*_*.!9)SQ?K'_VX
MYZ/4?7C7QS^')OH7\2:=%FXB7_3(D'+H/^6GU Z^WTKV6FLH92",@\$&OT+-
M,NHYIA98:MUV?9]'_730VE'F5F?-OP=^)7_")ZA_9FH2_P#$GNGR'8\6\A_B
M_P!T]_S]:^DE8,H(.0>017S3\7_ANWA#4VU"QB)T:Z?@*.('/\!]CV_*NF^#
M/Q6$*P^'M9GPG"6=U(>!Z1L?Y'\/2OSW(,TJY1B7DN9.UG:+Z>2OV?1_+TQA
M+E?+(]RHHIKL(U9F. HR:_5CH/FW1V_M;X^&0<C^U)6_! V/_0:^E*^9?@VW
M]H?%:&X;DM]IF_$@_P#Q5?35? \&OVF%KU_YZDG^",:>S8R2-9HV1U#HPVE6
M&01Z5\D_$'PJ_@SQ9=V"[EM]WG6S_P#3,G*\^H.1^%?7->9?'3P?_;WAD:G;
MQ[KS3<R' Y:(_?'X8#?@:Z.+<K_M# .K37OT]5Z=5]VOR'4CS(N^&_B9!=?#
M-_$%TP:XLXC'.F>6F7  _P"!$J?^!5S7P%\/S:A-J?BS4/WEU=R-'$[=\G,C
M#ZGY?^ FO&]$CU#6)(M!LI6V:A<1YB'W2XR Q^@)/X>U?76AZ/!X?TBSTZV&
M(+:(1K[X')/N3D_C7CY#B*V?UZ.(KKW</&W^*;TO\HZ^39,&YM-]"_69XFM_
MMGAO58,9\RUE3'U0UITR:,31.AZ,"I_&OTNI#VD)0?5&Y\A?#VZ^Q^-O#\Q.
M +N('Z,=I_G7U_7Q;!(=+U6.3HUK<!O^^'_^M7V?!,EQ#'+&VZ.10ZL.X(R#
M7Y;P%4M1Q%%[II_>FOT.>CLT257OKV+3;*XNIVV0P1M*[>B@9-6*\R^/?B0:
M3X/_ +.C?%QJ3^7COY:\N?Y#\:_1,QQD<OPE3%2^RK_/HOF]#>3LKG!_"&UE
M\:?$Z\UZZ7*P%[MLCH[DJB_@,_\ ?-?1->9_ '0AIO@LWS+B;4)FES_L+\JC
M]"?QKTRO$X7PLL-EL)U/CJ7F_66WX6(IJT0J"\LXM0LY[:9=\,R-&Z^JD8(J
M>BOK&E)69H?&NK:?=>$?$ES:ABEUI]SA)/=3E6_$8/XU];>&-<B\2>'[#4X?
MN7,2N1_=;^(?@<C\*\2_:'\-_8]<LM:C3$=XGDRD?\]$Z'\5_P#0:U?V>/%B
MM!=^'IWPZ$W-L">JG[ZCZ'!_$U^0Y#/^Q,[K99-VA/X?SC]Z=O4YH>[-Q/;*
M***_7SI"BBB@ HHHH **** "BBB@ JKJ-Q-::?<SV]J]]<1QL\=M&RHTK 9"
M L0H)/&2<<U:HH _,'XX?LM_M)_'KQ]>>*/$'ARS1I/W5G8IK%N8K* 'Y8D^
M?\2W\1))K@?^'>/QS_Z%FR_\&UM_\77Z^45]#3SS$TXJ$(Q27D_\SYRID.&J
MR<YRDV_-?Y'Y!_\ #O#XY_\ 0LV/_@VM_P#XNC_AW?\ '/\ Z%JQ_P#!M;__
M !5?KY16G]OXOM'[G_F9_P"KV$[R^]?Y'Y"?\.[_ (Y?]"U8_P#@VM__ (JC
M_AW?\<O^A;L/_!M;_P#Q5?KW12_M_%]H_<_\P_U>PG>7WK_(_(7_ (=W?'+_
M *%NP_\ !M;_ /Q5'_#N[XY?]"Y8?^#:W_\ BJ_7JBC^W\7VC]S_ ,P_U>P?
M>7WK_(_(;_AW;\<?^A<T_P#\&T'_ ,51_P .[?CC_P!"[I__ (-H/_BJ_7FB
MC^W\7VC]S_S'_J]@^\OO7^1^0W_#NWXX_P#0NZ?_ .#:#_&E_P"'=GQQ_P"A
M>T__ ,&T'^-?KQ11_;^+[1^Y_P"8?ZO8/O+[_P#@'Y#_ /#NOXX_]"]IW_@V
M@_QH_P"'=?QQ_P"A?T[_ ,&T'^-?KQ11_;^+[1^Y_P"8?ZO8/O+[_P#@'Y$?
M\.Z_CC_T+^F_^#:'_&C_ (=U_'#_ * &F_\ @VA_QK]=Z*/[?Q?:/W/_ ##_
M %>P?>7W_P# /R(_X=U?'#_H :;_ .#:'_&E_P"'=/QP_P"@#IG_ (-H?\:_
M7:BC^W\7VC]S_P P_P!7L'WE]_\ P#\B?^'=/QP_Z 6F?^#:'_&C_AW/\;_^
M@%IG_@UA_P :_7:BC^W\7VC]S_S#_5_!]Y??_P  _,WX6_LV?M9?!F93X3O(
M-/M VYM/DU>&:T?US"^5&?48/O7VA\)?&/QBNFALOB-\/].L'P VK:'JT4D1
M/JT#G<O_  %F^E>Q45YV(QTL5K4A&_=)I_F>EAL!'"Z4YRMV;NOR"BBBO,/4
M"BBB@ HHHH **** "BBB@ HHHH *RM<OM3L8XSINEC5';.Y3<+"$],DCG\*U
M:*SJ1<XN*DX^:M?\4U^ 'SKX@^$?C7Q/K=[JEU;6<4US(7*"Y!"CH%''8 "N
MP^'>C^-O 6GRZ?+HUKJ-FTAE39>JCHQZCD<CBO6J*^4PW#.%PF)>+HU9JH[W
M=XZWWO>-C-4TG=%+2KF[N[027EE]@GR08?-63 ['(XJ[117UL8N,4F[^?_#&
M@44450&;K5[J%C C:?IO]IREL&/SUBVC'7)KP[Q5\+/&OC'Q!=ZK<VEG;O.1
MMC^U A%  "YQSP*^@Z*\#-,FHYM%0Q$Y<J=[*R5_NO\ B1**EN>-_#GPUXV^
M'HNH#I-IJ%E<,)#&MZ$9& QD$CN,<>U>J:/>7UY;L]_I_P#9LH; C\Y9<CUR
MM:%%=&7Y;'+::HTJDG!;)V?XV3_$:CRZ!1117KE&-K^I:Q9;5TO1UU,LI)9[
MI854]@<@D_A7@VH?!;QIK&H75]<PV?GW,K2R?Z2/O,<G'%?25%?.9GD5#-VO
MK4Y66R322_"_WLB45+<\L^'UCXV\$:.-+N-$MM1M4=FB:.^5'3)R1R,$9R?Q
MKT6UNKR;3//FL?L]WM8_9?.5N1G W#CGC\ZO45Z&"P*P-)485).,59)VT_!/
M3S&ERZ'GOBF\\=ZQILMII6B6^EM*I1KF6^1W4'KM '!]Z\]\*?"?QEX1\06.
MK165E=/;L286N@-P(*D9QP<$\U]"45Y.*X?HXRO#$UZTW.'PZQTMKHE&WX:]
M27!-W;,_1[R^O;=WOM/.G2AL"/SEER,=<K6A117TT(N,4F[^;M^ED:!24M%6
M!X/\1?A/XC\3^+[_ %.QL;6.WF*A<W(#-A0-Q&."<=*M_#_PS\0? ,DL46GV
MM[I\IW/:R7:KAO[RGL?7CFO;:*^0CPQA:>+>.I5)QJ-MW377?3EV\C/D5[F;
MHM[J%]"[:AIO]F2*<+'YZR[AZY%9'BR^\2^3=6FBZ-'.SQ[8[R:[5%4D<G9C
M/%=317T=3#RJ4O9>TDGW7+?\K?<B^A\R?\*$\7%#F"T],?:1G^5>P>'=0\9Z
M9I5M::AX=@NY(46/[1#?HN\ 8!*D=?QKNZ*^?R_AO#97-SPE2<6]'K%W^^+(
M4%'8;&Q9%++M8CE<YQ[4ZBBOK#0JZEIUMJUC-9WD*7%M,I22-QD,*\.\3_L[
M7L=P\FA7D4]LQR+>[)5U]MP!#?CBO>Z*\3,LFP6;12Q4+M;-:-?/]'H3**EN
M>2>$8/B9X7A2TN+&TUBS0 ()KQ1(@'8/W'U!KH-?U'QGJFCW-I8^'8;&XG0Q
M_:)M01@@(P2 !R<5W=%12RET:+P\<14Y;6U<6[>3<;_B'+TN?/W@_P"%_C3P
M3X@MM5MK&QNFB#(T+70&Y6&",XX/O7MFAW^IWRR'4=+_ +,9<;5%PLP?UZ#B
MM6BC+,GI93%T\-4ER-WL[-7^Z_XBC%1V"FR1K*C(RAD88*GH1Z4ZBO>+/,?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
(% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>spry-20241113.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2024-11-12T15:17:06.6338+00:00 -->
<!-- Copyright (c) 2024 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://ars-pharma.com/20241113" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:spry="http://ars-pharma.com/20241113" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd" namespace="http://xbrl.sec.gov/dei/2024"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd" namespace="http://fasb.org/us-gaap/2024"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbase id="lnk">
        <link:roleRef roleURI="http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="spry-20241113.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
        <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SolicitingMaterial_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_WrittenCommunications_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre-commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Securities Act File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
          <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
          <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
        </link:labelLink>
        <link:presentationLink xlink:role="http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
          <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="49.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="50.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="51.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="52.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="53.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="54.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="55.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="56.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="57.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="58.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="59.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="60.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="61.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="62.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="63.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="64.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="65.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="66.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="67.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="68.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="69.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="70.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="71.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
          <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="72.0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
        </link:presentationLink>
      </link:linkbase>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>6
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.3</span><table class="report" border="0" cellspacing="2" id="idm45124402041056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Nov. 13, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001671858<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Nov. 13,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARS Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39756<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-1489190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">11682 El Camino Real<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 120<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92130<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(858)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">771-9307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SPRY<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>7
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
M##AM68]>'*F#!   SQ$  !@   !X;"]W;W)K<VAE971S+W-H965T,2YX;6R-
MF&]SXC80QK^*QNUTVID$6X;P)P5F"$FNF;O+<4![TW;Z0M@"-+$M5Y*!?/NN
M;&)SJ5GS!FRP'O^TNWI6]G OU8O><F[((8X2/7*VQJ2WKJN#+8^9;LF4)_#/
M6JJ8&3A5&U>GBK,P'Q1'KN]Y73=F(G'&P_RWF1H/968BD?"9(CJ+8Z9>[W@D
M]R.'.F\_S,5F:^P/[GB8L@U?</-[.E-PYI8JH8AYHH5,B.+KD3.AMW=^UP[(
MK_A#\+T^.29V*BLI7^S)4SAR/$O$(QX8*\'@:\>G/(JL$G#\>Q1URGO:@:?'
M;^J/^>1A,BNF^51&WT1HMB.G[Y"0KUD6F;G<_\:/$[JQ>H&,=/Y)]L6U'<\A
M0::-C(^#@2 62?'-#L= G [PSPSPCP/\G+NX44YYSPP;#Y7<$V6O!C5[D$\U
M'PUP(K%961@%_PH89\;W,L@@R(:P)"0/B1'FE3PE1;8A:D/7P$WLI6YP%+PK
M!/TS@L]RUR*T?45\S^]\/]P%MA+0+P']7*]]1F\J=UR1OR<K;12D\)\ZHD*A
M4Z]@Z_I6IRS@(P<*5W.UX\[XIQ]HU_L5X6N7?&U,?3R!Z(5Y!!\CMJFCP\>O
M6:0YPM$I.3JHSC%W4R!1+((<AOQ /O+7.B)<R?,\VNW1_DT?P;HIL6Y0L;*^
MEJ\IKV/!A_>O/R(0W1*B>QG$C"LA;9V'!%9++0^N5%9W4WGW2K3>)6F;\XVP
M!0Z,SRRN!<-U)O,%F6T9+-N 9T8$4%574 1!"V'LEXS]2QA!3:I4JMP8R,)
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M>ZC+N.HL?X;[:)'-M[#/)73)>UYN1]76^T$D7O!9QP<<GB-WPQ-',)^ Q1'
ML#P8 \PG>&%Y_J?]K-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,
MJ^AV&V6PQ>J69? 7CX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@
M\;J!1Y['NXWE 0^L"]CL0/YX'IBIN$^:0E<Q;M@)QI$\QQ"8Q?B,9AE2G0P^
M\?Y@IR1-\SR. !9GD*88 J<11S &P %#TG1X#SY['R73>RHY_U=3_ 102P,$
M%     @ ##AM69>*NQS     $P(   L   !?<F5L<R\N<F5L<YV2N6[#, Q
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M2P$"% ,4    "  ,.&U949(^QNT    K @  $0              @ &O
M9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  ,.&U9F5R<(Q &  "<)P
M$P              @ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0
M   (  PX;5F/7ARI@P0  ,\1   8              " @0P(  !X;"]W;W)K
M<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  ,.&U9GZ ;\+$"  #B#
M#0              @ '%#   >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    (  PX
M;5F7BKL<P    !,"   +              "  :$/  !?<F5L<R\N<F5L<U!+
M 0(4 Q0    (  PX;5D<.&7J/P$  #P"   /              "  8H0  !X
M;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  ,.&U9)!Z;HJT   #X 0  &@
M            @ 'V$0  >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"
M% ,4    "  ,.&U999!YDAD!  #/ P  $P              @ ';$@  6T-O
F;G1E;G1?5'EP97-=+GAM;%!+!08     "0 ) #X"   E%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="spry-20241113.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="spry-20241113.htm">spry-20241113.htm</File>
    <File>spry-20241113.xsd</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>false</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>13
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "spry-20241113.htm": {
   "nsprefix": "spry",
   "nsuri": "http://ars-pharma.com/20241113",
   "dts": {
    "inline": {
     "local": [
      "spry-20241113.htm"
     ]
    },
    "schema": {
     "local": [
      "spry-20241113.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 24
   },
   "report": {
    "R1": {
     "role": "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "C_722cc94d-c748-47cf-8ee4-45ed3f25c094",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20241113.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "C_722cc94d-c748-47cf-8ee4-45ed3f25c094",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "spry-20241113.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Securities Act File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://ars-pharma.com/20241113/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>14
<FILENAME>0000950170-24-125921-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-24-125921-xbrl.zip
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M[Y&L!7W'L8@B,4&?PYC&+*01ZE6]'L$P60.=1A'JRFH9ZHI,I%>"-XI&^SG
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MGKB41R#GYPP?O-3( VL:? 9,PX],:N#Y+P=Q,$A9:% Q8?WCS+$?QP;4<FQ
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M.&,:K,,43X,S;575G,>4[QCP77VO.!'<H4!(M7<!HRC#&\]L0Z2&:1Q1_2B
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MR3&)[OLNUGIR3*(\N2V?')/HCD_N":JYT$PPVCC*'_G 1*=JS!@]I_K@UN7
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M>2TR,#(T,3$Q,RYH=&U02P$"% ,4    "  ,.&U99E]"B-T)  !>?0  $0
M            @ '/%0  <W!R>2TR,#(T,3$Q,RYX<V102P$"% ,4    "  ,
M.&U93CKF=NPR  "XCP, #P              @ ';'P  <W!R>2UE>#DY7S$N
9:'1M4$L%!@     #  , NP   /12      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>spry-20241113_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="spry-20241113.xsd" xlink:type="simple"/>
    <context id="C_722cc94d-c748-47cf-8ee4-45ed3f25c094">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001671858</identifier>
        </entity>
        <period>
            <startDate>2024-11-13</startDate>
            <endDate>2024-11-13</endDate>
        </period>
    </context>
    <dei:EntityCentralIndexKey
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_2bd59650-8195-44e4-b1a5-4c25699d2cc6">0001671858</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_8078ef32-8095-4784-a2d8-8d85bc3076f8">false</dei:AmendmentFlag>
    <dei:DocumentType
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_0ae80446-f1d9-4a40-bcd9-1bcb14e8a308">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_c64cb2ab-ec3c-4bbf-b5f1-68797c5350f7">2024-11-13</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_0ab9245a-1592-49fa-98a8-4a878e45773a">ARS Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_c0eabaa9-eb1b-4d6c-92bf-181e8afd59a7">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_53e96947-c88b-4475-8711-593d59522937">001-39756</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_36cc84a1-6a64-4406-af2a-f3c8b08bd65c">81-1489190</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_c3f3e46b-b34d-48f9-891d-7d752c322696">11682 El Camino Real</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_2666731f-d3a3-41fe-8f06-23d9cf35af4c">Suite 120</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_ea418407-8983-42c6-a5f7-612f007fb8bb">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_78c3fb09-85fe-4c16-b374-edfa6b8faeed">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_d9082e8f-f9be-4970-9ffa-6fe96e0f9ed5">92130</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_5ff8fcea-60ff-43dc-848e-09bf48fafe91">(858)</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_97a97db6-1327-4dbd-8a32-a7aec92c8081">771-9307</dei:LocalPhoneNumber>
    <dei:WrittenCommunications
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_74e2f487-699a-41de-8bfe-4b58c6c91b04">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_7e0a3ef2-1cd5-482d-95d9-accde7837f0b">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_b6c825ea-d151-4446-b060-a237f4d0fc0a">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_524ed97e-28c9-4d18-9ea7-3b41cb563650">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_d92368f2-c38c-4c4e-a151-2ce63b95094f">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_21c9e9d6-4605-4f7d-b05e-a43131cef167">SPRY</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_784e40e1-d2c6-477e-8b83-4e2d2ce9e63f">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_db7af1c0-cc27-4da0-be98-a00f38b37b7c">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_722cc94d-c748-47cf-8ee4-45ed3f25c094"
      id="F_8092692a-94d5-4e60-9f77-aba1e0c1a906">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
